BioSpace News Archive

Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced exclusive license agreements with Shanghai-based Tolo Biotech

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Migraine is a disabling disease that costs families 70% more in health care expenses than families without a migraine sufferer

Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Deepa Pakianathan, Ph.D., as an independent member of its Board of Directors.

RAD Women (#RADxx), a networking group for the advancement of women in imaging informatics, today announced the winners of the 4th annual RADxx Awards.

-The Centers for Medicare &; Medicaid Services (CMS) announced the SpineJack implantable fracture reduction system qualified for the Transitional Pass-Through (TPT) payment as part of the 2021 Medicare Hospital Outpatient Prospective Payment System.

Over 30 abstracts to be presented at the virtual American Society of Hematology (ASH) Annual Meeting including new data from the MMRF CoMMpass Study and clinical trials

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, reports that its lead drug candidate, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes, has been featured on local TV

22nd Century Group, Inc. (NYSE American: XXII ), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it will be presenting at the 13 th Annual LD Micro Main Event Conference on Monday, December 14, 2020, at 9:20 a.m. ET. James A. Mish, chief executive officer of 22nd Century Group, will be presenting to a live, virtual

WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update to its shareholders: